SCHEMBL3883352

SCHEMBL3883352

O=C(Cl)C(=O)c1c(-c2ccccn2)cc2ccccn12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 3/20 0.50
BRD4 O60885 1/20 0.50
BRD2 P25440 1/20 0.50
BRD3 Q15059 1/20 0.50
BAZ2A Q9UIF9 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.45
L3MBTL1 Q9Y468 5/20 0.43
THRB P10828 1/20 0.43
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATM Q13315 1/20 0.38
POLB P06746 1/20 0.36
BRD9 Q9H8M2 2/20 0.36
KDM4E B2RXH2 4/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884093 0.82 SMN1; SMN2 (0.46) BAZ2BBRD4BRD2BRD3BAZ2A
SCHEMBL1645071 0.81 SMN1; SMN2 (0.48) BAZ2BBRD4BRD2BRD3BAZ2A
SCHEMBL3889228 0.80 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1645731 0.79 SMN1; SMN2 (0.68) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1646704 0.78 SMN1; SMN2 (0.47) BAZ2BBRD4BRD2BRD3BAZ2A
SCHEMBL3886464 0.78 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL8002223 0.77 SMN1; SMN2 (0.49) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1646968 0.77 SMN1; SMN2 (0.48) SMN1; SMN2L3MBTL1THRBMAPTHTT
SCHEMBL1644533 0.76 SMN1; SMN2 (0.46) BAZ2BBRD4BRD2BRD3BAZ2A
SCHEMBL3886862 0.76 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1THRBMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 BAZ2B 1160/4885BRD4 2165/4885BRD2 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.